drug
crizanlizumab
Marketedupdated 3mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
indications
investigational
Sickle Cell Disease
all catalysts(0)
nothing on the calendar yet
Trials studying crizanlizumab
- phase3Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
- —Managed Access Programs for SEG101, Crizanlizumab
- phase4Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- phase3A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- phase2A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
- phase2Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
- phase4An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
- phase2Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
News(2)
- Agios scraps sickle cell drugThe study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.biopharma_dive · 24d ago
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.biopharma_dive · 2mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that